Sirolimus Current Events

Sirolimus Current Events, Sirolimus News Articles.
Sort By: Most Viewed | Most Recent
Page 1 of 4 | 145 Results
Stents and going with the flow
In the first of three articles on sirolimus-eluting stents, in the February 1 issue of CMAJ, Yang and Moussa explain the mechanism of action of these types of stents and the clinical and scientific rationale behind their use within a wider context of interventional cardiology. (2005-01-31)

Sirolimus-releasing stents more effective than VBT for treating restenosis within a stent
David R. Holmes, Jr., MD, of Mayo Clinic, Rochester, Minn., and colleagues with the SISR trial compared the use of vascular brachytherapy (VBT - intra-coronary radiation therapy) with implantation of the sirolimus-eluting stent for the treatment of restenosis occurring within a previously placed bare-metal stent, in a study appearing in the March 15 issue of JAMA. Data on the relative merits of each approach are limited. (2006-03-12)

Anti-rejection drug may increase risk of diabetes after kidney transplant
For patients undergoing kidney transplantation, treatment with the anti-rejection drug sirolimus may lead to an increased risk of diabetes, reports a study in the July Journal of the American Society of Nephrology. (2008-05-22)

Grapefruit juice lets patients take lower dose of cancer drug
A glass a day of grapefruit juice lets patients derive the same benefits from an anti-cancer drug as they would get from more than three times as much of the drug by itself. The combination could help patients avoid side effects associated with high doses of the drug and reduce the cost of the medication. (2012-08-07)

Study highlights efficacy of sirolimus stents to prevent restenosis for PTS with CAD
Coronary stents coated with the immunosuppressive drug sirolimus are more likely to protect patients with coronary artery disease against future narrowing of coronary arteries (restenosis) than conventional metal stetns, conclude authors of a randomised trial in this week's issue of THE LANCET. (2003-10-02)

New biolimus stents, biodegradable polymer are as effective as sirolimus stents and durable polymer
Stents eluting biolimus from a biodegradable polymer represent a safe and effective alternative to a stent eluting sirolimus from a durable polymer in patients with chronic stable coronary artery disease or acute coronary syndromes. These are the conclusions of authors of an article published early online and in an upcoming edition of the Lancet, authored by Professor Stephan Windecker, Department of Cardiology, Bern University Hospital, Switzerland. (2008-09-01)

Sirolimus-eluting stent better than zotarolimus-eluting stent in everyday clinical practice
The widely used sirolimus-eluting stent is superior to the second-generation zotarolimus-eluting stent for patients in everyday clinical practice, concludes the SORT OUT III study published online first and in this week's edition of the Lancet. (2010-03-15)

Drug-releasing stents showing higher complication rate than clinical trials indicated
In a report in the May 4 JAMA, (2005-05-03)

Patients with rare lung disease face agonizing treatment dilemma
The drug sirolimus can slow progression of the lung disease LAM, while also causing potentially fatal complications in lung transplant patients. But research suggests a drug similar to sirolimus may be safe for LAM patients waiting for transplants. (2014-04-17)

Mayo Clinic study finds heart transplant patients benefit from new approach to immunosuppression
A new immunosuppression regimen for heart transplant patients can improve kidney function and prevent transplant coronary artery disease, according to two new Mayo Clinic studies. Mayo researchers will report their findings on April 26 at the International Society for Heart & Lung Transplantation Annual Meeting and Scientific Session in San Francisco. (2007-04-26)

Sirolimus therapy alleviates symptoms of lung disease LAM
Sirolimus, a drug currently used to help prevent transplant rejection, can improve lung function and quality of life in individuals living with the lung disease lymphangioleiomyomatosis (LAM), according to the results of a new study sponsored and conducted in part by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. (2011-03-16)

Stanford researcher dusts off old drug; uncovers new anti-rejection properties
Thirty years ago, researchers scooped some dirt on Easter Island and discovered bacteria that led to a potential anti-fungal drug. Little did they know that the drug - which languished on shelves after proving ineffective in early trials - would become popular in 1999 as a way to prevent rejection of transplanted organs. Now, new studies from Stanford University Medical Center have found that the drug can also protect blood vessels of transplanted hearts, preventing the leading cause of heart transplant failure. (2002-04-25)

Stents that release medication appear more effective than traditional stents
A type of coronary artery stent that releases a medication appears to result in better outcomes than traditional stents for heart attack patients, according to a study in the May 4 issue of JAMA. (2005-05-03)

Oncotarget: Sirolimus-eluting stents -- opposite in vitro effects on the clonogenic cell potential
The cover for issue 31 of Oncotarget features Figure 4, ''Concentration dose-response curves of sirolimus effect [55 nM-1 nM] on the number of cells per surviving colony in U2OS cell line after 2 weeks exposure,'' by Vasuri, et al. which reported that the authors evaluated the long-term effects of sirolimus on three different cell in vitro models, cultured in physiological conditions mimicking sirolimus-eluted stent, in order to clarify the effectiveness of sirolimus in blocking cell proliferation and survival. (2020-10-21)

Study: Sirolimus is effective, safe for treatment-resistant autoimmune blood conditions
The immunosuppressant sirolimus is an effective and safe steroid-sparing therapy for children and young adults with highly treatment-resistant autoimmune blood conditions, according to a study published online today in Blood, the Journal of the American Society of Hematology. This treatment is particularly effective in children with autoimmune lymphoproliferative syndrome, a chronic genetic disorder characterized by the buildup of white blood cells in the organs. (2015-10-26)

Best post-transplant drug regimen identified for patients with new kidneys
Patients treated with tacrolimus (TAC) and mycophenolate mofetil (MMF) had lower rejection rates and better kidney function. Multi-year study compared three commonly used immunosuppresive regimens. More than 16,000 US patients receive kidney transplants each year; preventing rejection requires a life-long delicate balance of medication (2011-07-29)

Switching immunosuppressants reduces cancer risk in kidney
Switching to a newer type of immunosuppressant drug may reduce the high rate of skin cancer after kidney transplantation, according to research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, Calif. (2009-10-31)

Comparison of anticoagulants for angioplasty show similar outcomes
In a comparison of anticoagulants and stents for use with angioplasty following a heart attack, the anticoagulants abciximab and tirofiban had similar outcomes for some cardiac measures within 90 minutes after the procedure, while patients who received stents that released the drug sirolimus had a lower risk of major adverse cardiac events within 8 months than patients who received uncoated stents, according to a JAMA study being released early online March 30. (2008-03-30)

The Lancet: European Society of Cardiology Congress 2014 media alert
The Lancet is pleased to announce that two papers will be published to coincide with presentation at the ESC Congress 2014, taking place in Barcelona, Spain, Aug. 30-Sept. 3, 2014. (2014-09-02)

Comparison of drug-releasing coronary stents show similar effectiveness
Use of coronary stents that release the drugs sirolimus or paclitaxel produced similar results in patients with new coronary artery lesions, according to a study in the February 22 issue of JAMA. (2006-02-21)

OHSU expert co-authors study finding treatment for rare lung disease
A new study has revealed a drug approved to prevent rejection in organ transplant patients helped treat a rare lung disease in women. (2011-04-11)

Transplant drugs may help wipe out persistent HIV infections
New research suggests that drugs commonly used to prevent organ rejection after transplantation may also be helpful for combating HIV. The findings, which are published in the American Journal of Transplantation, suggest a new strategy in the fight against HIV and AIDS. (2014-04-03)

Common cause for complications after kidney transplantation identified
The BK polyomavirus often causes complications after kidney transplantation. The research group of Professor Hans H. Hirsch from the Department of Biomedicine at the University of Basel has now been able to show, that the immunosuppressive drug Tacrolimus directly activates the replication of the virus and could thus be responsible for these complications. The American Journal of Transplantation has published the study. (2015-11-23)

Kidney transplant patients may benefit from going off of certain immunosuppressive drugs
Withdrawing certain immunosuppressive drugs following kidney transplantation prolongs survival and saves money compared with keeping patients on these medications for life, according to a study appearing in the September 2008 issue of the Journal of the American Society Nephrology. (2008-06-18)

A 'profound' success in treating children and young adults with rare blood disorders
Hematology researchers have safely and effectively treated children and young adults for autoimmune blood disorders in a multicenter clinical trial. In children with one of those conditions, autoimmune lymphoproliferative syndrome, all the patients showed a durable, complete response, with normal blood cell counts and rapid improvements, a result the study team called 'profound.' (2015-10-26)

REGiMMUNE presents enhanced efficacy data in preclinical transplantation models
REGiMMUNE Corporation today announced that its lead product candidate RGI-2001, in combination with a low-dose of Sirolimus, demonstrated enhanced efficacy in transplantation tolerance induction in models of skin transplantation and acute Graft-versus-Host disease (GvHD). This data is being presented today in a poster titled (2009-06-01)

Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
Dana-Farber researchers found an experimental drug combination for preventing graft-vs.-host disease was not significantly better than the standard regimen of care, but that the new combination could provide an alternative that could be preferable in certain scenarios. (2012-12-10)

New therapy found for rare lung disorder
Researchers at the University of Cincinnati and Cincinnati Children's Hospital Medical Center have found that the FDA-approved drug sirolimus, used primarily to prevent rejection in organ transplant patients, stabilized lung function in women with lymphangioleiomyomatosis. (2011-03-16)

Preliminary US study findings support excellent results with CYPHER Sirolimus-eluting Stent
Clinical investigators today reported preliminary findings at The Paris Course on Revascularization (PCR) documenting the excellent results of the CYPHER™ Sirolimus-eluting Stent in the first 400 patients enrolled in the landmark SIRIUS study. SIRIUS is a large-scale, randomized, double-blind, controlled clinical trial involving 53 U.S. treatment centers and 1,101 patients. The study was sponsored by Cordis Corporation, a Johnson & Johnson company. (2002-05-22)

Study finds patients with chronic total occlusions benefit from the CYPHER® Stent
Results from a study on chronic total occlusions in the coronary arteries show positive clinical outcomes in patients treated with the CYPHER® Sirolimus-eluting Coronary Stent compared to those treated with conventional bare metal stents. The six-month clinical and angiographic findings of the PRISON II trial (A Prospective Randomized Trial of Sirolimus-Eluting and Bare Metal Stents in Patients With Chronic Total Occlusions) were presented today at the Transcatheter Cardiovascular Therapeutics (TCT 2005) Conference. (2005-10-18)

Post-transplant drug may also help patients with common genetic kidney disease
The immunosuppressive drug sirolimus considerably improves the kidney health of patients with autosomal dominant polycystic kidney disease (ADPKD), according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. The results suggest that this agent may be a promising treatment option for patients with ADPKD -- the most common genetic kidney disease and a major cause of kidney failure. (2010-05-13)

Common drug-releasing coronary stents appear to have similar clinical outcomes
A comparison of use of the first two commercially available drug-releasing coronary stents (for the medications sirolimus and paclitaxel) among patients in (2008-01-29)

Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation. (2012-06-26)

Study examines use of stent with bioabsorbable polymer
Three-year data demonstrated that satisfactory clinical and safety outcomes of sirolimus eluting stents with a biodegradable polymer were sustained in a real world setting. The results were presented at the 22nd annual Transcatheter Cardiovascular Therapeutics scientific symposium, sponsored by the Cardiovascular Research Foundation. (2010-09-21)

FDA approves drug-coated stents
The US Food and Drug Administration (FDA) today approved the use of a drug-coated stent to treat patients with clogged cardiac arteries. These stents -- metal mesh tubes used as scaffolding to keep blood vessels open and unclogged -- are laced with low doses of the drug sirolimus to help prevent clogging. (2003-04-24)

TCT update: Late-breaking clinical trial data will shape the future of interventional cardiology
Transcatheter Cardiovascular Therapeutics is the annual scientific symposium of the Cardiovascular Research Foundation. Attended by over 10,000 participants each year, TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in the field of interventional cardiology and vascular medicine. (2008-09-18)

New study results suggest better outcomes with the CYPHER® Stent than brachytherapy
Results from the SISR trial, a multi-center, randomized study of the CYPHER® Sirolimus-eluting Coronary Stent versus radiation from within a vessel (brachytherapy) in patients with bare-metal in-stent reblockage (restenosis), were presented today at the TCT 2005 Scientific Symposium. The study showed that patients who received the CYPHER® Stent had a significantly lower incidence of target vessel failure at nine months post-procedure compared with patients who received brachytherapy. The SISR trial was sponsored by Cordis Corporation. (2005-10-17)

LEADERS (Limus Eluted from A Durable versus ERodable Stent coating)
In the first study of its kind, a drug-eluting stent with a biodegradable polymer applied only to the outer surface has been demonstrated as safe and effective as one of the most established and widely used types of DES with a durable polymer, in equivalent conditions to everyday clinical practice. (2008-08-31)

The future of interventional cardiology presented at TCT 2008
Transcatheter Cardiovascular Therapeutics is the annual scientific symposium of the Cardiovascular Research Foundation. Attended by over 10,000 participants each year, TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in the field of interventional cardiology and vascular medicine. (2008-10-07)

Northwell Health's Feinstein Institute discovers cancer treatment for transplant patients
Kenar D. Jhaveri, M.D., and Richard Barnett, M.D., Feinstein Institute for Medical Research scientists and Northwell Health Department of Internal Medicine nephrologists, published a Letter to the Editor in the prestigious New England Journal of Medicine, which profiles a novel drug combination with the potential to help prevent rejection of a donor kidney in transplant patients undergoing cancer treatment. (2017-01-18)

Page 1 of 4 | 145 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to